These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36240081)
1. Opinion & Special Article: Glioma Classification: How to Interpret Molecular Markers in a Diffuse Glioma Pathology Report. van der Meulen M; Ramos RC; Mason WP; Von Deimling A; Maas SLN Neurology; 2022 Nov; 99(20):903-908. PubMed ID: 36240081 [TBL] [Abstract][Full Text] [Related]
2. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted. Santosh V; Rao S Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases. Lee B; Hwang S; Bae H; Choi KH; Suh YL Brain Pathol; 2024 Sep; 34(5):e13234. PubMed ID: 38217295 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting. Jain S; Gupta P; Shankar KB; Singh R; Siraj F J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575 [TBL] [Abstract][Full Text] [Related]
7. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. Sonoda Y Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379 [TBL] [Abstract][Full Text] [Related]
8. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. Malzkorn B; Reifenberger G Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086 [TBL] [Abstract][Full Text] [Related]
9. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258 [TBL] [Abstract][Full Text] [Related]
10. Updates on the WHO diagnosis of IDH-mutant glioma. Reuss DE J Neurooncol; 2023 May; 162(3):461-469. PubMed ID: 36717507 [TBL] [Abstract][Full Text] [Related]
11. Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors. Kurokawa R; Kurokawa M; Baba A; Ota Y; Pinarbasi E; Camelo-Piragua S; Capizzano AA; Liao E; Srinivasan A; Moritani T Radiographics; 2022; 42(5):1474-1493. PubMed ID: 35802502 [TBL] [Abstract][Full Text] [Related]
13. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective? Weller M; Reifenberger G Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376 [TBL] [Abstract][Full Text] [Related]
14. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. Macaulay RJ Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765 [TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105 [TBL] [Abstract][Full Text] [Related]
16. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
17. [Classification and Diagnosis of Adult-Type Diffuse Gliomas]. Ohno M; Sugino H No Shinkei Geka; 2023 Sep; 51(5):760-770. PubMed ID: 37743327 [TBL] [Abstract][Full Text] [Related]
18. [World Health Organization Classification of Central Nervous System Tumours, 5 Ichimura K No Shinkei Geka; 2023 Mar; 51(2):349-363. PubMed ID: 37055056 [TBL] [Abstract][Full Text] [Related]
19. Distinct metabolic hallmarks of WHO classified adult glioma subtypes. Björkblom B; Wibom C; Eriksson M; Bergenheim AT; Sjöberg RL; Jonsson P; Brännström T; Antti H; Sandström M; Melin B Neuro Oncol; 2022 Sep; 24(9):1454-1468. PubMed ID: 35157758 [TBL] [Abstract][Full Text] [Related]
20. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]